Ironwood Pharma (IRWD) Misses Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Ironwood Pharma (IRWD) Misses Q1 EPS by 12c

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

May 2, 2019 7:00 AM EDT

Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019

First quarter 2019 revenue of $69 million driven primarily by LINZESS® (linaclotide) collaboration revenue; reiterates full year 2019 revenue guidance

LINZESS prescription demand grew 14% year-over-year in first quarter 2019

Late-stage GI pipeline continues to progress; IW-3718 is enrolling patients in phase III trials and MD-7246 phase II trial expected to initiate in May 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More